Saturday 17 October 2026
Export GRCE’s income statement to Excel — free account
Grace Therapeutics, Inc.
GRCE Healthcare Biotechnology
In the quarter to June 2026, EPS fell 333.3% and free cash flow fell 78.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.
1.89
0.06
−3.08%
Follow GRCE
| Mar '17 | Mar '18 | Mar '19 | Mar '20 | Mar '21 | Mar '22 | Mar '23 | Mar '24 | Mar '25 | Mar '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | 0.00 | — | — | — | — | — |
Altman Z-Score |
— | — | — | — | 3.31 | — | — | — | — | — |
P/S ratio |
— | — | — | — | 356.47 | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | 5.59 | — | — | — | — | — |
P/FCF ratio |
— | — | — | — | 0.00 | — | — | — | — | — |
P/Operating CF |
— | — | — | — | (40.45) | — | — | — | — | — |
P/B ratio |
— | — | — | — | 1.28 | — | — | — | — | — |
Price to Tangible BV |
— | — | — | — | 1.38 | — | — | — | — | — |
EV/Sales |
— | — | — | — | 66.48 | — | — | — | — | — |
EV/EBITDA |
— | — | — | — | 0.00 | — | — | — | — | — |
EV/Operating CF |
— | — | — | — | (0.93) | — | — | — | — | — |
EV/FCF |
— | — | — | — | (0.92) | — | — | — | — | — |
Quick Ratio |
4.67 | 1.34 | 1.97 | 2.00 | 38.80 | 13.56 | 8.41 | 14.09 | 11.53 | 7.92 |
Current Ratio |
4.76 | 1.42 | 2.05 | 2.50 | 39.50 | 13.89 | 8.59 | 14.26 | 11.77 | 8.10 |
Net Debt/EBITDA |
1.05 | 0.39 | 0.76 | 0.64 | 3.92 | 2.80 | 0.54 | 1.79 | 1.33 | 1.53 |
Debt/Assets |
5.52% | 7.02% | 3.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.06 | 0.20 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.66 | 0.58 | 0.63 | 0.90 | 0.73 | 1.76 | 0.38 | 0.96 | 1.56 | 1.14 |
Capex/Depreciation |
0.00 | (0.17) | (0.23) | (0.14) | (0.07) | — | (40.58) | (587.73) | 0.00 | 0.00 |
Interest Coverage |
(179.36) | (13.45) | (6.94) | (22.73) | (5.04) | (202.45) | (212.01) | — | — | — |
| (47.44%) | (147.88%) | (450.89%) | (212.26%) | (57.33%) | (11.98%) | (48.15%) | (19.82%) | (14.91%) | (11.94%) | |
| (40.36%) | (90.69%) | (143.65%) | (85.40%) | (46.13%) | (10.28%) | (40.85%) | (16.86%) | (13.17%) | (11.24%) | |
ROIC |
0.00% | (763.15%) | 0.00% | 0.00% | 0.00% | (15.08%) | (81.36%) | (20.74%) | (23.44%) | (14.76%) |
Return on Tangible Assets |
(96.50%) | (382.91%) | (239.96%) | (194.40%) | (32.32%) | (23.23%) | (163.30%) | (57.51%) | (46.01%) | (51.13%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 986.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 2,129.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 3,399.49% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.49 | 0.44 | 0.17 | 0.19 | 0.00 | 0.64 | 0.62 | 0.67 | 0.68 | 0.74 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 598.98% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | — | — | — | 0.78 | — | — | — | — | — |
Graham Number |
— | — | — | — | 0.00 | — | — | — | — | — |
Earnings Yield |
— | — | — | — | (27.01%) | — | — | — | — | — |
Free Cash Flow Yield |
— | — | — | — | (20.21%) | — | — | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.47) | (26.80) | (21.91) | (13.02) | (5.79) | (2.81) | (2.14) | (1.29) | (1.23) | (0.54) |
Capex per Share |
0.00 | (0.97) | (0.47) | (0.18) | (0.03) | 0.00 | (0.68) | (0.68) | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.47) | (27.78) | (22.38) | (13.20) | (5.82) | (2.81) | (2.82) | (1.97) | (1.23) | (0.54) |
Cash per Share |
0.66 | 17.61 | 22.77 | 8.08 | 24.57 | 7.11 | 3.75 | 2.41 | 1.83 | 1.03 |
Shareholders Equity per Share |
1.47 | 17.61 | 9.76 | 7.37 | 22.52 | 17.63 | 9.14 | 6.48 | 5.51 | 3.87 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.47 | 17.61 | 9.76 | 7.37 | 22.52 | 17.63 | 9.14 | 6.48 | 5.51 | 3.87 |
Free Cash Flow |
(5.20) | (10.12) | (25.32) | (23.27) | (14.39) | (17.23) | (20.94) | (18.80) | (14.90) | (8.87) |
Working Capital |
6.04 | 2.18 | 14.30 | 11.07 | 60.79 | 42.02 | 25.88 | 22.33 | 20.78 | 15.23 |
Capital Expenditures |
(1.93) | (0.35) | (0.53) | (0.32) | (0.07) | — | (5.03) | (6.46) | — | — |
Net Current Asset Value |
4.82 | (4.09) | 2.12 | 8.60 | 55.57 | 24.93 | 18.12 | 12.45 | 17.33 | 14.62 |
EV/EBIT |
— | — | — | — | 0.00 | — | — | — | — | — |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.35 | — | 0.00 | 0.00 | — | — |
Price to Operating Income |
— | — | — | — | 0.00 | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.97 | 0.95 | 1.11 | 1.13 | 10.74 | 0.00 | 1.19 | 0.46 | 0.47 | 0.88 |
Cash ROIC |
(21.09%) | (71.84%) | (66.35%) | (85.44%) | (12.36%) | (11.34%) | (21.85%) | (22.18%) | (16.79%) | (10.97%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.36 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
1.82 | 0.75 | 0.27 | 0.24 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — | — |
Average Days of Payables |
55.17 | 916.09 | 1,925.44 | 1,151.48 | 7,170.33 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — | — |
Average Receivables |
0.14 | 0.37 | 0.89 | 0.87 | 0.54 | 0.54 | 0.68 | 0.76 | 0.42 | 0.07 |
Average Payables |
1.06 | 2.76 | 8.77 | 9.81 | 4.41 | 2.32 | 3.25 | 2.51 | 1.81 | 2.04 |
Average Assets |
19.60 | 18.50 | 27.40 | 29.87 | 42.66 | 95.54 | 103.87 | 76.21 | 72.65 | 69.32 |
Average Common Equity |
16.67 | 11.34 | 8.73 | 12.02 | 34.33 | 81.97 | 88.11 | 64.85 | 64.18 | 65.25 |
Columns are period end dates